Boston Strategics Corporation Announces Key Agreement In Translational Oncology With Molecular Response

BOSTON, Oct. 14, 2014 /PRNewswire/ -- Boston Strategics Corporation (BSC), an integrated clinical-stage drug research and development (R&D) company, Boston, MA, today announced that it has entered into an agreement with Molecular Response (MRL), a privately held molecular diagnostic services company and a leader in the identification of target populations for high value therapeutics. In collaboration with MRL, BSC designs and manages for pharmaceutical drug development programs to improve POS (Probability Of Success) identifying patient sub-populations using patient-derived tumor xenografts (PDX), leveraged by MRL’s proprietary ‘living’ cell bank of primary tumor cells.

This translational program and collaboration is another example of a BSC collaboration, whereby BSC optimizes and executes the global strategy of key pharmaceutical partners’ drug development programs. Utilizing BSC’s internal oncology development expertise and its ability to leverage the “True” Open Innovation network to collaborate with the best resources around the world, BSC continues to deliver more efficient and superior outcomes to key partners in treatment of cancer patients worldwide.

“We are excited to work with Boston Strategics to further refine the efficacy package of novel therapeutics for pharmaceutical partners and help the precision of their programs with more targeted approach to patient selection. The collaboration with these partners is proof of our success and continued commitment to enable further evaluation of cancer therapeutics in better characterized models with use of our high content cell-based platforms and exclusive patient-derived xenografts,” said Cyrus K. Mirsaidi, Molecular Response CEO.

“The selection of Molecular Response as a member of Boston Strategics’ ‘True’ Open Innovation platform, and access to their vast bank of characterized near patient models strengthens the ability of our network partners to address translational challenges and assess efficacy of compounds earlier in the life cycle of their programs,” said Dr. Keizo Koya, Boston Strategics, CEO. “This approach combined with access to a large and well annotated primary tumor bank will allow foundational work for biomarker development, target population selection, and new indication mining for novel therapeutics.”

About Molecular Response:
Molecular Response is a leader in the utilization of large, clinically relevant tumor banks and predictive patient-derived xenografts (PDX) that help advance high value therapeutics through intelligently designed, biomarker driven in vitro and in vivo models. Our goal is to reduce risk and cost of therapeutic drug development for our partners by use of fully characterized efficacy models to create a clinically predictive knowledge base while fully integrated into existing pharmaceutical development processes and programs; Our results allow for the most informed decisions with best chance of success to advance therapeutic programs.

For additional information please visit www.molecularresponse.com.

About Boston Strategics Corporation (BSC):
BSC is an integrated drug R&D company with experience in developing, managing and optimizing global drug development programs from late discovery, through translational research, first-in-man or proof-of-concept clinical studies. Its mission is to continuously improve patient health care by changing the drug R&D paradigm using “True” Open Innovation platform.

SOURCE Boston Strategics Corporation